ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.055 AUD 1.85% Market Closed
Market Cap: 111.3m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

ImpediMed Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ImpediMed Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
ImpediMed Ltd
ASX:IPD
Gross Profit
AU$9m
CAGR 3-Years
10%
CAGR 5-Years
25%
CAGR 10-Years
13%
R
Respiri Ltd
ASX:RSH
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cyclopharm Ltd
ASX:CYC
Gross Profit
AU$18.8m
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
7%
Cochlear Ltd
ASX:COH
Gross Profit
AU$1.7B
CAGR 3-Years
16%
CAGR 5-Years
9%
CAGR 10-Years
12%
Optiscan Imaging Ltd
ASX:OIL
Gross Profit
AU$629.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
29%
EMvision Medical Devices Ltd
ASX:EMV
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ImpediMed Ltd
Glance View

Market Cap
111.3m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.079 AUD
Undervaluation 30%
Intrinsic Value
Price

See Also

What is ImpediMed Ltd's Gross Profit?
Gross Profit
9m AUD

Based on the financial report for Jun 30, 2024, ImpediMed Ltd's Gross Profit amounts to 9m AUD.

What is ImpediMed Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
13%

Over the last year, the Gross Profit growth was -8%. The average annual Gross Profit growth rates for ImpediMed Ltd have been 10% over the past three years , 25% over the past five years , and 13% over the past ten years .

Back to Top